Homocysteine is a precursor of S-adenosylmethionine (AdoMet) and a metabolite of Sadenosylhomocysteine (AdoHcy). The ratio of AdoMet / AdoHcy, defined as the methylation potential (MP), indicates the flow of methyl groups within the cells. Chronic elevations of total homocysteine (tHcy) in plasma correlate with increased AdoHcy concentrations, decreased MP, and impaired DNA methylation. However, the influence of acute hyperhomocysteinemia on MP is unknown.
Introduction
Homocysteine is a sulphur-containing, non-proteinogenic amino acid biosynthesized from methionine. It plays a key role between the folate cycle and the activated methyl cycle (Figure 1 ). Homocysteine can be transsulfurated to cystathionine, remethylated to methionine, synthesized to S-adenosylhomocysteine (AdoHcy), or released into the extracellular space.
During remethylation, homocysteine acquires a methyl group from N-5-methyltetrahydrofolate or from betaine to form methionine. A considerable proportion of methionine is then converted to S-adenosylmethionine (AdoMet), the major methyl donor to a variety of acceptors including guanidinoacetate, nucleic acids, neurotransmitters, phospholipids and hormones. The product of these methylation reactions, AdoHcy, inhibits most of the AdoMet-dependent methyltransferases and is therefore rapidly hydrolyzed to adenosine and homocysteine (5) . The hydrolysis of AdoHcy to adenosine and homocysteine by AdoHcy hydrolase (E.C. 3.3.1.1; AdoHcyase) is the only metabolic pathway leading to formation of homocysteine in vertebrates.
This reaction is reversible and favors synthesis of AdoHcy. However, under physiological conditions the metabolic flux is directed towards homocysteine formation because of removal by further metabolism (17, 31) .
The ratio of AdoMet / AdoHcy, defined as the methylation potential (MP), is considered to be a reliable indicator of the flow of methyl groups transferred from AdoMet to methyl acceptors within the cells (18) . As recently shown, chronic elevations of plasma tHcy correlate with increased AdoHcy levels and with a decreased MP in plasma. The low MP is associated with a decreased methylation of lymphocyte DNA (36). This state may alter methylationdependent gene regulation and may have unwanted effects on a variety of organ systems.
Homocysteine is assumed to be an independent marker for increased cardiovascular risk (13, 20) , and DNA hypomethylation may be one of the responsible mechanisms.
Elevated tHcy plasma concentrations can be the result of reduced enzymatic activity of many enzymes involved in homocysteine metabolism because of vitamin deficiencies or genetic mutations mainly of cystathionine -synthase (CBS) or 5,10-methylenetetrahydrofolate reductase (MTHFR) (25) . A well-examined polymorphism of the latter enzyme is the C677T transition. If this transition occurs in both alleles resulting in a 677TT genotype, plasma tHcy concentration is approximately 2.6 µmol/l higher compared to 677CC carriers (3) . Furthermore, hyperhomocysteinemia is regularly seen in chronic renal failure (CRF). However, the underlying mechanisms have not been fully elucidated (22) .
In order to assess the time frame in which hyperhomocysteinemia can affect MP and thus DNA methylation, we induced acute hyperhomocysteinemia by oral administration of exogenous L-homocysteine in healthy male volunteers. With this study design we wanted to determine whether a short time exposure to homocysteine is sufficient to induce changes in MP in erythrocytes and global DNA methylation in lymphocytes. In addition, we wanted to measure renal homocysteine excretion in relation to homocysteine plasma levels. Fux -20.04.2005 
Materials and Methods

Subjects
Healthy non-smoking male volunteers (n=14; age 21-26 years, body mass 63-98 kg, BMI 20.0-26.6 kg/m²) participated in the study. The study was conducted with an open, randomized, placebo-controlled 2-period cross-over design. The study was approved by the local Ethics Committee, and written informed consent was obtained from all participants.
Individuals with a known allergic disposition or with cardiovascular risk factors including diabetes mellitus, blood pressure readings >160/95 mmHg, or clinical evidence of cardiovascular disease were excluded. The mean blood pressure values were 121 ± 7.9 (systolic) and 79 ± 7.3 (diastolic) mmHg. No volunteer had a systolic blood pressure above 130 mmHg or a diastolic blood pressure above 90 mmHg. Thus, all volunteers were normotensive. All subjects were non-vegetarians and free from pharmacotherapy and intake of vitamin preparations. Their plasma concentrations of folate, pyridoxine (vitamin B 6 ), cobalamin (vitamin B 12 ), and tHcy were within the normal ranges. For inclusion of the volunteers into the study, we set an upper limit of plasma tHcy of 15.0 µmol/l.
Preparation of Study Medication
The homocysteine solution was prepared as described by Guttormsen et al. (1993) (10) .
Powdered L-homocysteine thiolactone hydrochloride (65.1 µmol/kg of body weight; molecular weight 153.6 g/mol; Sigma-Aldrich Chemie GmbH, Munich, Germany) was dissolved in 5 ml of 5 mol/l sodium hydroxide solution and allowed to stand for 5 min to open the thiolactone ring. Then 5 ml of 5 mol/l HCl were added for neutralization, and the pH was adjusted to 4-5. A mixture of water (90 ml) and apple cider (100 ml) (to mask the unpleasant taste of homocysteine) was added, to give a total volume of 200 ml. The mixture was prepared Fux -20.04.2005 immediately before administration under the supervision of a pharmacist. The placebo control consisted of 100 ml water and 100 ml apple cider.
Study Protocol
The volunteers were required to abstain from alcohol and caffeine for the 24 hours preceeding each study day. They entered the study after an overnight fast in a quiet, temperature-controlled room (22 ± 2°C). They were requested to drink approximately 300 ml/h water throughout the whole study day. After 5 min of supine rest, blood pressure and pulse rate were measured. To obtain blood samples, two 1.7-mm-diameter cannulae were inserted into an antecubital vein on either side for infusions and contralateral blood sampling. Thereafter, venous blood was withdrawn for pre-dose determination of tHcy, AdoMet, AdoHcy, inulin, and DNA methylation in lymphocytes. A separate blood sample was withdrawn for the genotyping of MTHFR (C677T polymorphism).
Clearance protocols were started with a 5 min inulin (Inutest ® , Fresenius GmbH, Graz, Austria) loading infusion of 50 ml 0.9% sodium chloride solution (Delta Pharma, Pfullingen, Germany) containing 1,5 g inulin per m² body surface (7) . Directly afterwards, a continuous infusion of inulin (6.25 g per m² body surface) was administered at a rate of 50 ml/h throughout the entire duration of clearance periods. Simultaneously, an infusion of 0.45% sodium chloride and 2.5% glucose (Delta Pharma, Pfullingen, Germany) was started at a rate of 3 ml/h per kg body weight. Clearance periods were performed at various time intervals, whereby blood withdrawal was made at the respective mid-point of each urine collection period. The different clearance periods were carried out according to the time course of tHcy plasma levels following the oral load. After one hour, when urine flow and plasma inulin were stabilized, a first 1-hour urine collection period was carried out to obtain the basal inulin clearance value before the administration of study medication (i.e. homocysteine vs. placebo). From there on, the infusion rate of the 0.45% sodium chloride and 2.5% glucose solution was adapted at the end of each clearance period to match urinary flow rate. Fux -20.04.2005 The study medication (i.e. 200 ml homocysteine solution versus 200 ml of placebo) was prepared immediately before administration and was ingested orally in less than 2 min.
According to the subjects' body weights (63-98 kg), the administered homocysteine doses ranged between 4.1 and 6.4 mmol (mean: 4.9 mmol). Then, blood samples were collected at +0.25 (15 min Blood pressure and pulse rate were recorded at 0, +1, 2, 3, 4, 5, 6, 8, 10, and 12 h. Standardized meals, poor in protein and vitamins, were given at +4 and +10 h. Subjects were discharged 12 h after the administration of study medication. The blood samples of +24 and +48 h were performed ambulatorily with a single-use butterfly needle. This procedure was repeated in one of the following weeks (maximum interval of 3 weeks) in a randomized cross-over design.
Analytical Methods
Homocysteine measurement
Whole blood for tHcy plasma concentration was collected in 3 ml Sarstedt tubes 
Urine analysis
Urine samples were stored at -25°C for a maximum of 6 months. Urinary tHcy concentrations were determined by HPLC, using a homocysteine assay by BioRad Laboratories (Munich, Germany) with the following modification: The internal standard of the reagent kit was replaced by mercaptopropionic acid to avoid interferences with unknown urinary compounds (B Proksch, unpublished observations). The lower limit of quantification was 1.5 µmol/l.
Clearance measurement
Clearance measurements are usually performed with the widely used polyfructosan inulin. In our study, we used the branched sinistrin (Inutest ® ) which is easier to handle than the linear inulin due to its better water solubility. In this text, sinistrin is referred to as inulin which is the more common term. Inulin concentrations in plasma and urine were determined by a colorimetric method using Seliwanoff's reagent (a solution of resorcinol and HCl) (34).
Clearances were calculated according to standard formulae and normalized to a body surface area of 1.73 m² for glomerular filtration rate (GFR).
Metabolite determination
AdoMet and AdoHcy concentrations were measured in perchloric acid extracts. Whole blood (2 ml) dropping out of the cannula was collected in tubes containing 5 ml of 0.6 N Fux -20.04.2005 perchloric acid at 0°C. The tubes were shaken thoroughly, placed on ice, and centrifuged within 10 min at 3,350 x g for 10 min at +4°C. For AdoMet and AdoHcy measurement in erythrocytes, whole blood was collected in 3 ml Sarstedt tubes containing EDTA, and immediately centrifuged at 680 x g for 5 min at +4°C. One ml of erythrocyte sediment was transferred into 4 ml 0.6 N perchloric acid at 0°C, shaken thoroughly, placed on ice, and centrifuged at 3,350 x g for 10 min at +4°C. All samples and standards were supplemented with a known amount of N-6-methyladenosine as internal standard. The supernatant was adjusted to a pH between 5.5 and 6.0 by adding 2 M K 2 CO 3 / 1 M KH 2 PO 4 . The precipitated potassium perchlorate was discarded after centrifugation at 20,000 x g, and the supernatant was applied onto solid-phase extraction column (BondElut, ICT, Bad Homburg, Germany). Elution of the compounds was performed with 0.1 M HCl, and the eluate was analyzed by reversed-phase chromatography with UVdetection according to Delabar et al. (6) with the following modifications: The binary solvent system consisting of solvent A (10 mM ammonium dihydrogenphosphate, 0.6 M heptanesulfonic acid sodium salt in 3% methanol) and solvent B (like solvent A and in addition 10% acetonitrile) delivered the following gradient: Immediately after sample injection, a linear gradient was started to increase solvent B to 15% with a transition rate of 1.2%/min and to 70% with a transition rate of 7.5%/min. Thereafter, solvent B was kept at 70% for 5 min. Before the next sample injection, solvent A was kept at 100% for 10 min to reequilibrate the system. Thus, the chromatogram was completed within 30 min. Remote control, data acquisition and quantification of peak areas were performed with the Peak Simple Software 3.12 by SRI Inc.
Global DNA-methylation
Whole blood for assessment of DNA methylation in lymphocytes was collected in two 8 ml Sarstedt tubes containing EDTA. Preparation of lymphocytes was performed with Ficollgradient (Bio-Chrom AG, Berlin, Germany). Global DNA methylation was determined as described by Pogribny et al. (23) . Genomic DNA was isolated using DNeasy Tissue Kit 
Results
Homocysteine kinetics
tHcy plasma concentrations at pre-dose were 8.9 ± 1.5 µmol/l (Figure 2) . The volunteers were administered a mean homocysteine dose, depending on body weight, of 754 ± 100 mg, i.e. 4,910 ± 649 µmol. Relevant tHcy kinetic parameters in plasma, whole blood, and erythrocytes were c max (90.4 ± 12, 72.4 ± 13, and 68.4 ± 29 µmol/l), t max (34 ± 11, 64 ± 16, and 77 ± 28 min), AUC (0-48 h) (486 ± 69, 492 ± 125, and 470 ± 311 µmol*h/l), and half-life (257 ± 41, 328 ± 45, and 470 ± 313 min), respectively. Twelve hours after homocysteine administration a mean amount of 110.6 ± 32 µmol was recovered in the urine, which corresponds to 2.3 ± 0.7% of the orally administered homocysteine dose (Figure 3 ). Renal homocysteine clearance reached a maximum of 10.8 ± 4 ml/min per 1.73 m² body surface one hour after homocysteine administration (Table 1 ) and fell subsequently to 1.5 ± 0.8 ml/min per 1.73 m² body surface 12 hours after homocysteine administration.
Inulin clearance
Inulin clearance at pre-dose was 91.3 ± 14.1 ml/min per 1.73 m² body surface (in the homocysteine group) and 100.0 ± 27.5 ml/min per 1.73 m² body surface (in the placebo group), respectively. Homocysteine intake did not cause any significant change in GFR, compared to placebo.
AdoMet and AdoHcy concentrations in whole blood
AdoMet and AdoHcy pre-dose values in whole blood were 2.0 ± 0.4 µmol/l and 217.6 ± 61 nmol/l, respectively (Table 1) . One hour after the administration of homocysteine, whole blood values of AdoMet and AdoHcy were not significantly changed (2.1 ± 0.5 µmol/l and 256 ± 80 nmol/l, respectively). Compared to whole blood measurements during placebo study days (AdoMet pre-dose: 1.9 ± 0.3 µmol/l, +1 h: 1.9 ± 0.3 µmol/l; AdoHcy pre-dose: 211 ± 53 nmol/l, +1 h: 231 ± 80 nmol/l), these changes in AdoMet and AdoHcy whole blood concentrations were significantly different in the paired t-test, but not in the ANOVA test. All other differences of Fux -20.04.2005 AdoMet and AdoHcy whole blood concentrations between time points after homocysteine administration and pre-dose measurements were not significantly different to placebo. The absolute values ranged between 2.2 ± 0.4 µmol/l (maximum; at +2 h) and 2.1 ± 0.3 µmol/l (minimum; at +4 h) for AdoMet values and between 256 ± 79 nmol/l (maximum; at +1 h) and 200.0 ± 48 nmol/l (minimum; at +4 h) for AdoHcy values. When the respective ratios AdoMet post-dose / AdoMet pre-dose and AdoHcy post-dose / AdoHcy pre-dose were calculated, no significant differences between verum and placebo were observed. When AdoMet and AdoHcy values or AdoMet and AdoHcy post-dose / pre-dose ratios were correlated with the respective tHcy plasma concentrations of each time point assessed, no significant differences between verum and placebo were observed. MP in whole blood was 10.2 ± 4 at pre-dose (Table 1) . After homocysteine administration, MP values ranged between 8.8 ± 2.8 (minimum; at +1 h) and 10.9 ± 3.5
(maximum; at +4 h). All the differences between time points after homocysteine administration and pre-dose measurements were not significantly different to placebo. When the respective ratios MP post-dose / MP pre-dose were calculated, no significant differences between verum and placebo were observed. When MP values or MP post-dose / pre-dose ratios were correlated with the respective tHcy plasma concentrations of each time point assessed, no significant differences between verum and placebo were observed.
AdoMet and AdoHcy concentrations in erythrocytes
AdoMet and AdoHcy pre-dose values in erythrocytes were 4.0 ± 0.9 µmol/l and 323 ± 129 nmol/l, respectively (Table 1) . After homocysteine administration, AdoMet values ranged between 4.0 ± 0.9 µmol/l (minimum; at +1 h) and 4.5 ± 1.0 µmol/l (maximum; at +24 h), and AdoHcy values ranged between 353 ± 86 nmol/l (maximum; at +1 h) and 300 ± 100 nmol/l (minimum; at +4 h). All the differences between time points after homocysteine administration and pre-dose measurements were not significantly different to placebo. When the respective ratios AdoMet post-dose / AdoMet pre-dose and AdoHcy post-dose / AdoHcy pre-dose were calculated, no significant differences between verum and placebo were observed. When AdoMet and AdoHcy Fux -20.04.2005 values or AdoMet and AdoHcy post-dose / pre-dose ratios were correlated with the respective tHcy plasma concentrations of each time point assessed, no significant differences between verum and placebo were observed. MP in erythrocytes was 14.1 ± 6.1 at pre-dose. After homocysteine administration, values ranged between 11.8 ± 4.4 (minimum; at +1 h) and 16.7 ± 11.1 (maximum; at +4 h). All the differences between time points after homocysteine administration and pre-dose measurements were not significantly different to placebo. When the respective ratios MP post-dose / MP pre-dose were calculated, no significant differences between verum and placebo were observed.
When MP values or MP post-dose / pre-dose ratios were correlated with the respective tHcy plasma concentrations of each time point assessed, no significant differences between verum and placebo were observed.
DNA methylation status in lymphocytes
In the cytosine extension assay, the extent of genome-wide methylation in lymphocytes was determined by 3 H-dCTP incorporation. The values at pre-dose were 17.5 ± 4.7 * 10³ dpm/µg DNA (in the homocysteine group) and 17.2 ± 3.8 * 10³ dpm/µg DNA (in the placebo group), respectively ( Table 1) . After homocysteine administration, a maximum of 21.9 ± 10 * 10³ dpm/µg DNA was reached after 48 hours. In the placebo group, a slight increase of 3 HdCTP incorporation upon 19.0 ± 1.7 * 10³ dpm/µg DNA (after 8 hours) was noted. However, the difference in methylation status between verum and placebo was not significant. Thus, global DNA methylation is not affected by acute hyperhomocysteinemia.
C677T/MTHFR genotyping
Seven subjects (50%) were heterozygous carriers of the 677T-genotype (CT), while the other 7 subjects (50%) were homozygous carriers of the wild type allele (CC). There were no significant differences in the measured parameters (tHcy, AdoMet, AdoHcy, and DNA methylation) between the CC and the CT genotype of MTHFR with one exception being a slightly but significantly elevated content of AdoMet in erythrocytes of CT carriers compared to the CC wild type. This difference was not only found at all time points, but also during the placebo treatment and during homocysteine loading as well.
Adverse events
Except of transient headache in one of the subjects, no adverse events were reported.
There were no clinically relevant changes of blood pressure or pulse rate. One volunteer experienced an anaphylactic reaction after 4 minutes of inulin infusion before any homocysteine was administered (9) . Subsequently, he was excluded from the study and was replaced by another volunteer. Fux -20.04.2005 
Discussion
Homocysteine is assumed to be an independent marker for increased cardiovascular risk (13, 20) . With a prevalence of 5-7% in the general population, hyperhomocysteinemia is considered to play a role in the genesis of premature atherosclerosis. However, a causal relationship between hyperhomocysteinemia and cardiovascular disease remains to be established. The recently published VISP (vitamin intervention for stroke prevention) trial in 3680 adults to study the effects of a vitamin-rich diet on recurrent cerebral infarction (primary outcome), coronary heart disease events and death (secondary outcomes) did not change the endpoints during a 2-year period, although tHcy was lowered by 2 µmol/l (28) . A variety of other mechanisms of Hcy-induced atherosclerosis including DNA hypomethylation have been described (2, 29) .
In the present study, we wanted to assess whether acute hyperhomocysteinemia can induce similar changes as found in chronic hyperhomocysteinemia (36) have shown that c max of tHcy in erythrocytes was lower than in plasma and was reached at a later time point than in plasma. According to former studies (11, 30) , the influence of the volunteers' protein-poor diet on postprandial changes in tHcy concentrations is negligible.
Urinary homocysteine excretion is very low as shown in studies with animals and humans (1, 22) . This low excretion rate of homocysteine is the consequence of its metabolism Fux -20.04.2005 by remethylation and transsulfuration (4, 22) and its high protein binding in humans (24) .
Assuming a protein binding of homocysteine of 80% in humans, 20% of tHcy enter the tubular fluid by glomerular filtration. However, in our study, only 2% of the administered homocysteine dose were recovered in urine within 12 hours. This is in line with the findings of Guttormsen et al. (12) who have shown in 19 cobalamin and folate deficient volunteers with hyperhomocysteinemia (67.1 ± 39.5 µmol/l) and with normal renal function that unchanged urinary excretion of homocysteine in 24 hours was about 6.5 ± 3.0% of an orally administered homocysteine dose (12) . Our data show that the excretion of tHcy into the urine increases transiently up to >60% of the calculated filtered load during acute hyperhomocysteinemia.
These findings indicate that the tubular uptake of homocysteine by basic amino acid transporter is saturable.
Although animal studies have demonstrated significant renal uptake and metabolism of homocysteine (1, 15) , the relevance of these findings in humans has been questioned, and renal metabolism of homocysteine appears marginal in humans (32). Furthermore, the contribution of impaired homocysteine excretion to hyperhomocysteinemia in renal failure seems to be very small. Hyperhomocysteinemia, frequently observed in CRF patients, may be explained by the loss of homocysteine metabolizing capacity of the whole body (26, 33) . The role of the kidney in the development of hyperhomocysteinemia, however, is incompletely understood at present (19) . Our finding that the renal homocysteine clearance increased from the basal level of 0.5 ml/min to 10.8 ml/min (Table 1) When focusing on safety aspects of acute hyperhomocysteinemia achieved by a single oral homocysteine load, such a procedure may be considered not harmful as much as MP and global DNA methylation were unchanged. In addition, we did not observe in our study any adverse effects which are likely to be caused by the intake of homocysteine. Thus, the oral administration of homocysteine in the range of the used doses (65.1 µmol/kg body weight) is well tolerated and may be considered safe.
In our study, the phenotyping of the C677T mutation of the MTHFR gene showed a distribution of 50:50 between homozygous (CC) and heterozygous allele carriers (CT). Both Fux -20.04.2005 genotypes did not differ in their response to an acute challenge of hyperhomocysteinemia. This applies to kinetics of tHcy concentrations in blood and urine, AdoMet in whole blood, AdoHcy in whole blood and erythrocytes, and to DNA methylation. However, we found one significant difference between the two genotypes which was an elevated content of AdoMet in erythrocytes of CT carriers, independent of tHcy plasma levels. Apparently, this difference did not affect the response to Hcy loading of both genotypes.
Concerning further investigations of the influence of tHcy on MP, the question about an exogenous induction of chronic hyperhomocysteinemia may be raised. Because of the fast catabolism of homocysteine with a half-life of approximately 4 hours, it would be hardly feasible to maintain chronic and stable plasma concentrations over a longer period (e.g. several days) by administering oral homocysteine doses. Intravenous administration would be also problematical to perform due to the lack of data about administration in humans and due to the unstable nature of homocysteine in terms of storage. The induction of chronic hyperhomocysteinemia by a methionine loading test or administration of folate antagonists for an investigation of MP, however, would induce additional changes in AdoMet and AdoHcy metabolism masking direct effects of elevated Hcy levels in plasma. In order to assess the meaning of the MP in clinical studies on homocysteine metabolism, it appears to be necessary to measure simultaneously AdoMet and AdoHcy also in settings when folic acid, pyridoxine or cobalamine are administered (27) .
In summary, acute hyperhomocysteinemia did not change AdoMet, AdoHcy, and the MP in both, whole blood and erythrocytes. Moreover, no induction of DNA hypomethylation in lymphocytes was observed. Although chronic elevation of tHcy has been shown to affect MP and DNA methylation, acute elevation of tHcy concentration in plasma above 20 µmol/l for 8 hours is not sufficient to change MP and to induce DNA hypomethylation in lymphocytes. Only a small amount of administered homocysteine (2.3%) was recovered in urine, while the rest is assumed to be subject to metabolism. hours after homocysteine load Cumulative urinary Hcy excretion (µmol)
